Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat

Psychopharmacology

Volumn 199, Issue 1, 2008, Pages 99-108

  Dupre, Kristin B ^a   Eskow, Karen L ^a   Steiniger, Aimee ^a   Klioueva, Anna ^a   Negron, Giselle E ^a   Lormand, Lydia ^a   Park, John Y ^a   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

5 HT1A; Dopamine; Dyskinesia; L DOPA; NMDA; Parkinson's disease

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; BENSERAZIDE; DIZOCILPINE; GLUTAMIC ACID; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DYSKINESIA; INVOLUNTARY MOVEMENT; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

3,4-DIHYDROXYPHENYLACETIC ACID; 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; EXCITATORY AMINO ACID ANTAGONISTS; HYDROXYINDOLEACETIC ACID; INJECTIONS, INTRAPERITONEAL; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; MOTOR SKILLS; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN; SEROTONIN AGONISTS; STEREOTYPED BEHAVIOR;

EID: 46149088212     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1135-6     Document Type: Article

References (57)

1. Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S et al (2005) Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58:193-199
2. Arai R, Karasawa N, Geffard M, Nagatsu I (1995) l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 195:195-198
3. Arai R, Karasawa N, Nagatsu I (1996) Dopamine produced from l-DOPA is degraded by endogenous monoamine oxidase in neurons of the dorsal raphe nucleus of the rat: an immunohistochemical study. Brain Res 722:181-184
4. Ba M, Kong M, Ma G, Yang H, Lu G, Chen S et al (2006) Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of l-DOPA-induced motor complications. Brain Res 1127:177-184
5. Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM et al (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 20:932-936
6. Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R (2006) 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis 23:77-86
7. Bibbiani F, Oh JD, Chase TN (2001) Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57:1829-1834
8. Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 196:422-429
9. Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD (2006) MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur J Neurosci 23:2669-2676
10. Blanchet PJ, Konitsiotis S, Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13:798-802
11. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2003) Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Disord 14:404-416
12. Campbell BM, Kreipke CW, Walker PD (2006) Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat. Neuroscience 137:505-517
13. Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819-1833
14. Castaneda E, Fleming S, Paquette MA, Boat K, Moffett J, Stachowiak EK et al (2005) Assessment of recovery in the hemiparkinson rat: drug-induced rotation is inadequate. Physiol Behav 84:525-535
15. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236-243
16. Chang JW, Wachtel SR, Young D, Kang UJ (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88:617-628
17. Chase TN, Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23:S86-S91
18. Crossman AR, Peggs D, Boyce S, Luquin MR, Sambrook MA (1989) Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacol 28:1271-1273
19. Dupre KB, Eskow KL, Negron G, Bishop C (2007) The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 1158:135-143
20. Eskow KL, Gupta V, Alam S, Park JY, Bishop C (2007) The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 87:306-314
21. Frechilla D, Cobreros A, Saldise L, Moratalla R, Insausti R, Luquin M et al (2001) Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39:288-296
22. Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow WE et al (2007) Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 22:179-186
23. Hallett PJ, Standaert DG (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 102:155-174
24. Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P (2006) In MPTP treated primates, the selective 5-HT1a agonist (R)-(+)-8-hydroxy-DPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J Pharmacol Exp Ther 319:1225-1234
25. Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 20(Suppl 11):S11-S16
26. Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M (2001) Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 76:1346-1353
27. Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M et al (2002) Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 54:133-137
28. Kilpatrick IC, Jones MW, Phillipson OT (1986) A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 46:1865-1876
29. Lane EL, Cheetham SC, Jenner P (2005) Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp Neurol 197:284-290
30. Lievens JC, Salin P, Nieoullon A, Kerkerian-Le Goff L (2001) Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA and protein expression in the rat striatum. J Neurochem 79:893-902
31. Loschmann P, De Groote C, Smith L, Wullner U, Fischer G, Kemp JA et al (2004) Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol 187:86-93
32. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132
33. Maeda T, Kannari K, Shen H, Arai A, Tomiyama M, Matsunaga M et al (2003) Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci Lett 343:17-20
34. Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN (1996) MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 736:202-205
35. Matsubara K, Shimizu K, Suno M, Ogawa K, Awaya T, Yamada T et al (2006) Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 1112:126-133
36. Mignon L, Wolf WA (2002) Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl) 163:85-94
37. Mignon L, Wolf WA (2005) 8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 16:699-703
38. Mignon L, Wolf WA (2007) Postsynaptic 5-HT(1A) receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for Parkinson's disease. Psychopharmacology (Berl) 192:49-59
39. Nash JE, Brotchie JM (2000) A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J Neurosci 20:7782-7789
40. Nash JE, Hill MP, Brotchie JM (1999) Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp Neurol 155:42-48
41. Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O et al (2004) Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27:58-62
42. Olsson M, Nikkhah G, Bentlage C, Bjorklund A (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15:3863-3875
43. Paxinos G, Watson W (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic, San Diego
44. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G et al (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501-506
45. Pisani A, Centonze D, Bernardi G, Calabresi P (2005) Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord 20:395-402
46. Queiroz CMT, Alcantara FB, Yague AML, Bibancos T, Frussa-Filho R (2002) Acute buspirone abolishes the expression of behavioral dopaminergic supersensitivity in mice. Braz J Med Biol Res 35:237-242
47. Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X et al (2000) Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol 417:181-194
48. Robelet S, Melon C, Guillet B, Salin P, Kerkerian-LeGoff L (2004) Chronic l-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. E J Neuroscience 20:1255-1266
49. Samadi P, Gregoire L, Morissette M, Calon F, Tahar AH, Dridi M et al (2008) mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Dis (in press)
50. Santiago M, Matarredona ER, Machado M, Cano J (1998) Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum. J Neurosci Res 52:591-598
51. Taylor JL, Bishop C, Walker PD (2005) Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav 81:887-893
52. Taylor JL, Bishop C, Ullrich T, Rice KC, Walker PD (2006) Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology 50:761-768
53. Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M (2005) A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to l-DOPA in a rodent model of Parkinson's disease. Neurosci Res 52:185-194
54. Tremblay M, Salin P, Soghomonian JJ (1995) Effect of 6-OHDA lesions on striatal mRNA levels encoding for glutamate receptor subunits. Neuroreport 6:2225-2229
55. Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natte R, Chase TN (1998) A trial of extromethorphan in parkinsonian patients with motor response complications. Mov Disord 13:414-417
56. Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD (2004) NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 47:184-194
57. Yamato H, Kannari K, Shen H, Suda T, Matsunaga M (2001) Fluoxetine reduces l-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport 12:1123-1126